#### 1 Musashi-1 Enhances Glioblastoma Cell Migration and Cytoskeletal

2

### **Dynamics through Translational Inhibition of Tensin3**

3 Hsiao-Yun Chen<sup>1</sup>\*, Liang-Ting Lin<sup>2,3,6</sup>\*, Mong-Lien Wang<sup>2,4</sup>, Benoit Laurent<sup>7</sup>, Chih-

4 Hung Hsu<sup>7</sup>, Chih-Ming Pan<sup>4,9</sup>, Wan-Ru Jiang<sup>3</sup>, Pau-Yuan Chen<sup>8</sup>, Hsin-I Ma<sup>10</sup>, Yi-Wei

5 Chen<sup>1,11</sup>, Pin-I Huang<sup>1,11</sup>, Arthur Chiou<sup>5</sup>, Shih-Hwa Chiou<sup>1,2,3,4,12</sup>

6

# **Supplementary Information**

#### 7 SUPPLE. FIGURE LEGEND

#### 8 Supple. Figure 1. MSI1 promoted GBM cells migration.

9 (A) 05MG cells transiently transfected with siRNA against MSI1 (siMSI1#1 and 10 siMSI1#2) or scrambled siRNA control (siCON), and (C) U251 cells transiently transfected with Flag-tagged MSI1 (FlagMSI1) or Flag control (Flag) were subjected 11 12 to Western blotting to assess MSI1 protein levels. (B) MSI1-depleted 05MG cells and (D) MSI1-overexpressed U251 cells were subjected to a 24-hour Transwell migration 13 14 assay. The number of migratory cells were counted and presented as percentages 15 relative to the controls. All values are mean + SEM. \*, P < 0.05 (relative to the control 16 group).

# Supple. Figure 2. MSI1-regulated genes indicated the relationship with cell migration pathway through bioinformatic analysis

(A) The gene list was analyzed by DAVID (https://david.ncifcrf.gov/) and illustrated
by QuickGO (https://www.ebi.ac.uk/QuickGO/) based on the significance of each GO
term using False discovery rate (FDR) as the criterium. (B) Both gene expressive
profiles from microarray and RIP-seq were demonstrated as log ratio and FPKM on a
X-Y plot and the genes with higher correlation between the two axes were highlighted
and further subjected to Gene Ontology analysis;

# Supple. Figure 3. MSI1 suppressed TNS3 translation through binding to 3'UTR of TNS3.

27 (A) 05MG cells transiently transfected with siRNA against MSI1 (siMSI1#1 and 28 siMSI1#2) or scrambled siRNA control (siCON) were subjected to Western blotting to 29 assess TNS3 and MSI1 protein levels. (B) Schematic diagram of human TNS3 mRNA 30 and the designed locations of amplified regions for RNA-Chip assay. (C) Schematic 31 representation of the reporter constructs containing the firefly luciferase coding 32 sequence fused to wildtype or mutated TNS3-3'UTR. The predicted binding site are 33 noted in colored ovals and the mutated residues are marked with a cross in the ovals. (D) 05MG cells were transfected with siMSI1 for 24 hours or (E) U251 cells were 34 35 transfected with FlagMSI1 for 24 hours and treated with 10 µg/ml of cycloheximide 36 (CHX) to block protein synthesis. Cellular proteins were harvested at indicated time 37 points after CHX treatment, and analyzed by Western blot (top). The intensity of TNS3 38 blot at each time point were calculating and presented as relative percentage in 39 comparison to the 0 hours' time point (Bottom).

# 40 Supple. Figure 4. MSI1 promoted cell migration through regulation TNS3/RhoA41 GTP signaling pathway in GBM.

42 (A) MSI1- and TNS3-depleted 05MG cells were subjected to a TransWell migration 43 assay. (B) MSI1- and TNS3-depleted 05MG cells were subjected to wound-healing 44 assay for 10 hours. (C) MSI1 and TNS3 protein levels were assessed in 05MG cells 45 transiently transfected with siMSI1#1 and/or siTNS3#1 using Western blotting. Wound 46 healing assay was performed in MSI1- and TNS3-depleted 05MG cells, and the number 47 of migratory cells were calculated and shown in the graphs. (D-E) MSI1- and TNS3depleted 05MG cells were seeded in 3.5-cm plates before using time lapse microscopy 48 49 for single-cell tracking (1 frame/5 min for 24 hr). The tracks of single cell were shown 50 in the left panel and the mean tracks of 15 cells were shown in the middle panel. The 51 mean motility and speed of cells was determined by the manual tracking plugin of 52 Image J in three independent analyses and shown as bar charts in the right. (F) MSI1-53 and TNS3-depleted 05MG cells were stained for F-actin (red) and DAPI (blue). The 54 ratio of mean aspect (defined as the ratio of the length of major and minor axes, AR) 55 were shown in the right (n = 100). (G) MSI1 regulated cell viscoelasticity through 56 inhibiting TNS3. The elastic modulus (G') and viscous modulus (G"; at 10 Hz) were 57 analyzed by MetLab software. Data are expressed as mean  $\pm$  SEM. All values are mean + SEM. \*, P < 0.05 (relative to the control group). #, P < 0.05 (relative to the siTNS3) 58

- 59 group).
- Supple. Figure 5. Uncropped blots from original scanned raw data of designatedfigures.
- 62

#### 63 MATERIALS AND METHODS

#### 64 Transfection

65 Plasmid transfection was carried out using jetPEI DNA transfection reagent (Polyplus 66 jetPEI®, Cat #101-10, DNA Transfection reagent, Huntingdon, UK) according to manufacturer's instructions. siRNA against MSI1 (siMSI1#1: SASI\_Hs01\_00145278, 67 siMSI1#2: SASI\_Hs01\_00145277), TNS3 (siTNS3#1: SASI\_Hs01\_00166414, 68 siTNS3#2: SASI\_Hs01\_00166415 ) and scrambled siRNA control (MISSION® siRNA 69 70 Universal Negative Control #1) were purchased from SIGMA siRNA smart pools. 71 Transient siRNA transfection was carried out using INTERFERin siRNA transfection 72 reagent (Polyplus INTERFERin®, Cat #409-10, siRNS transfection reagent) according 73 to the manufacturer's instruction. Cell-based experiments were performed after 48 74 hours of incubation. The information of plasmids was listed in Suppl. Table 1.

#### 75 Western blotting

76 All total protein lysates were collected with RIPA buffer (Millipore, Cat #20-188, RIPA Lysis Buffer, 10X) containing 1% protease inhibitor (SIGMA, Cat #05892791001 77 ROCHE, cOmplete<sup>™</sup> ULTRA Tablets, Mini, EDTA-free, EASYpack Protease Inhibitor 78 79 Cocktail). Equal amount of total proteins was separated by electrophoresis on 80 SDS/PAGE. After the proteins were transferred onto a polyvinylidene difluoride 81 membrane (Millipore, Cat # IPVH00010, Immobilon-P Membrane, PVDF, 0.45 µm, 82 26.5 cm x 3.75 m roll), the blots were incubated in blocking buffer (1 X PBST and 5% skim milk) for 1 hour at room temperature and then hybridized with primary antibodies 83 84 overnight at 4°C, followed by incubation with horseradish peroxidase-conjugated 85 secondary antibody for 1 hour at room temperature. The blots were obtained by X-ray 86 film exposure. The primary antibodies used in this study were anti-Flag (Sigma-Aldrich 87 Co. LLC., St. Louis, MI, USA, F1804), anti-Musashi1 (cell signaling, #5663), anti-88 TNS3 (SIGMA, #SAB4200416), anti-RhoA (cell signaling, #2117) and anti-β-actin 89 (sigma, A5316). The secondary antibody used in this study were anti-Rabbit-HRP (cell 90 signaling, #7074) and anti-Mouse-HRP (cell signaling, #7076).

#### 91 Luciferase reporter assay

92 U251 cells were co-transfected with pMIR-control constructs, TNS3-3'UTR-WT, TNS3-3'UTR-mut1, TNS3-3'UTR-mut2 and Flag-control or Flag-MSI1 using jetPEI 93 94 DNA transfection reagent in 24-well plate. The pMIR-REPORT  $\beta$ -gal control Plasmid, 95 containing  $\beta$ -gal luciferase, was used as an internal control. The cells were cultured at 96 37 °C in 5 % CO<sub>2</sub> for additional 24 hrs. The cells were harvested and the luciferase 97 activity was measured using dual luciferase assay system (Thermo, Cat#T1003, Dual-98 Light® luminescent reporter gene assay system) according to the manufacturer's 99 instructions.

#### 100 Quantitative real-time PCR (qPCR)

101 Total RNA were isolated from GBM cells using TRIzol (Life Technologies Inc., Carlsbad, CA, USA) followed by phenol:chloroform purification and ethanol 102 103 precipitation. Reverse transcription were carried out using SuperScript III reverse 104 transcriptase (Life Technologies Inc., Carlsbad, CA, USA). Oligonucleotides (Suppl. 105 Table II) were designed using Primer Express 2.0 (Applied Biosystems, Foster City, CA, USA). The real-time-PCR was performed with power SYBR Green PCR Master 106 107 Mix (Applied Biosystems, Foster City, CA, USA) according to manufacturer's instruction. Signals were detected with 7900HT Fast Real-time PCR system (Applied 108 109 Biosystems, Foster City, CA, USA). The expression level of each gene was normalized to endogenous beta-actin and experimental control through  $\Delta$ Ct methods. 110

#### 111 Immunofluorescence (IF) staining

112 Cells were sub-cultured on glass coverslips for 24 hrs. The cells were fixed with 4 % 113 paraformaldehyde for 10 mins, permeabilized with 0.1% Triton X-100 for 10 mins, NP-114 40 for 10 mins, and incubated with blocking buffer (5% BSA) for 1 hour at room 115 temperature. The samples were immune-stained with the indicated primary antibodies 116 overnight at 4°C, followed by FITC-labeled or PE-labeled secondary antibodies for 117 imaging. The primary antibodies used in this study were anti-F-Actin (Thermo, Cat # 118 R415, Rhodamine Phalloidin), DAPI (SIGAM, Cat #D9542).

#### 119 Immunohistochemistry staining and immunoblotting (IHC)

120 Tumor specimens from mice and GBM patients were fixed with 4% paraformaldehyde

121 (Sigma-Aldrich Co., St. Louis, MI, USA). Sections were deparaffinized and rehydrated,

- and subjected to antigen retrieval by boiling for 30 mins in 10 mmol/L (pH 6) citrate
- buffer (Sigma-Aldrich Co., St. Louis, MI, USA). Sections were cooled in TPBS for 10
- 124 mins before treating with 3% H<sub>2</sub>O<sub>2</sub>. Sample were blocked in 5 mg/ml BSA (Sigma-
- 125 Aldrich Co., St. Louis, MI, USA) for 30 mins before hybridizing with 1/100 diluted
- 126 primary antibodies anti-Flag (Sigma-Aldrich Co. LLC., St. Louis, MI, USA, F1804),
- 127 anti-TNS3 (SIGMA, #SAB4200416) overnight at 4°C. Signals were amplified by the
- 128 TSA Biotin System (PerkinElmer, Waltham, MA) following the manufacturer's
- 129 instruction and the samples were counterstained with hematoxylin. The sections were
- 130 examined under Olympus BX61 microscope (Olympus Corp., Tokyo, Japan), and three
- 131 field of views were randomly selected and photographed for evaluation.

132

| 4 2 2 | 0 1    | <b>T</b> 11 T | T • 4 • 41  | •         | 1.0      | 1 1     |              |
|-------|--------|---------------|-------------|-----------|----------|---------|--------------|
| 133   | Suppl. | Table I.      | List of the | e primers | used for | plasmid | construction |

| Name              | Sequence (5'-3')                     |
|-------------------|--------------------------------------|
| MSI-F             | ATGGAGACTGACGCGCCCCAGCCCG            |
| MSI1-R            | TCAGTGGTACCCATTGGTGAAGGCT            |
| MSI1-F-HindIII    | AGAAGCTTATGGAGACTGACGCGCCCCAGC       |
| MSI1-R-BamHI      | AGGATCCTCAGTGGTACCCATTGGTGAAGG       |
| TNS3-3'UTR-F      | TTCGTATCAAAGGTCATGATTGGT             |
| TNS3-3'UTR-R      | GGGTACACAAATACCGTCTCACGG             |
| TNS3-3'UTR-MutA-F | CGTCTTCTCTGCCTTAGGCAGGCATATTTTTACTTT |
| TNS3-3'UTR-MutA-R | GAAAGTAAAAATATGCCTGCCTAAGGCAGAGAAGAC |
| TNS3-3'UTR-MutB-F | CTATAAATCTTTTGTCGCAGCATTTTCTCTGCTCC  |
| TNS3-3'UTR-MutB-R | GGAGCAGAGAAAATGCTGCGACAAAAGATTTATAG  |

### 134

# 135 Suppl. Table II. Sequences of the primer used for real-time PCR analysis

| Gene Name | Forward sequence      | Reverse sequence       |
|-----------|-----------------------|------------------------|
| MSI1      | TTGACAAAACCACCAACCGG  | CCTCCTTTGGCTGAGCTTTCTT |
| TNS3      | AGACGATGACCCCTGGCTAT  | CGTGGTTCACGTCCTCCTTT   |
| β-actin   | GCGTGACATTAAGGAGAAG   | GAAGGAAGGCTGGAAGAG     |
| GAPDH     | AGAAGGCTGGGGGCTCATTTG | AGGGGCCATCCACAGTCTTC   |

### 136

# 137 Suppl. Table III. Sequences of the primer used for RNA ChIP analysis

| TNS3      | Forward sequence      | Reverse sequence       |
|-----------|-----------------------|------------------------|
| mRNA Seq. |                       |                        |
| 813-1111  | TGCAGCCTTCCCAAAAACGG  | CGAGCGGTATTTCTTGTGGTAG |
| 1243-1523 | ATTAGTCTTCTCTGCCACGCC | CAGACAAGGTGTGGTCACTGT  |
| 1760-2032 | GCTGCTCTGAAGGATCGGG   | TCGACTCCCAAAAGTCCGCT   |
| 2310-2561 | CACATCCCCCTGACACACAG  | TGTCTGGAGACACAGAGCCA   |
| 2733-3021 | AATGTGCATGGGGAAAGGCT  | CAGCTTCGTGGTTCACGTC    |
| 3329-3559 | TCAGAGCTCCAGGCTCCTTT  | CCACCGTGAGAAAGTTGTGG   |
| 3779-4029 | CCCAAATGTCCTTCCCGACT  | TGGCCAAATCTCCAGCTTTCT  |

| 4229-4526 | GAAAGTTCTCCCCAGACGGC  | ACTTCCTGTCTTGTGGGTCC      |
|-----------|-----------------------|---------------------------|
| 4858-5102 | AACATCACCGTGAATTGGCCT | AAGCATGGCAGTCACTCGG       |
| 5271-5448 | CGAAGGTTTGTGCAAGTCAGG | TTCTCCTCTCGGTCCTCACAG     |
| 5726-5935 | TTCCCCGATTGTGGATGACT  | CACAACCACACATGGTCCCC      |
| 6285-6514 | CCATTCTTAGGCCACACTGGT | AATGAGGCACTTGGTTTGGTG     |
| 6778-7027 | AGTGCAGGCCAGGTTCCTTA  | ATTCCCCGATGCCCTTGACC      |
| 7291-7548 | CCTGGGGAGTAAATGCGGAG  | AAGGAGCAGAGAAAATGACTATACA |









